Elutia plans NXT-41x FDA submission this quarter after rabbit study results
Elutia said a GLP rabbit study of its drug-coated surgical matrix hit its performance goals, supporting a fourth-quarter 2026 FDA filing, while it reported $26 million in new non-dilutive funding.
SEC filing